Top 10 Influencers in 2025$Novo Nordisk AS(NVO.US) Good news is coming 😝🎉
Novo Nordisk's Alhemo subcutaneous injection has been approved by the FDA to prevent or reduce the frequency of bleeding in patients aged 12 and older with hemophilia
Novo Nordisk AS announced that its Alhemo (concizumab) subcutaneous injection has been approved by the U.S. FDA as a once-daily preventive treatment aimed at preventing or reducing the bleeding frequency in patients aged 12 and older with hemophilia A or B with factor inhibitors. Alhemo is the first subcutaneous treatment regimen for this population, and clinical trials have shown that patients receiving Alhemo treatment experienced an 86% reduction in annual bleeding rates
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
